Key statistics
On Friday, Supernus Pharmaceuticals Inc (S49:DUS) closed at 33.40, -4.02% below its 52-week high of 34.80, set on Nov 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 33.40 |
---|---|
High | 33.40 |
Low | 33.40 |
Bid | 33.80 |
Offer | 34.40 |
Previous close | 34.80 |
Average volume | 58.10 |
---|---|
Shares outstanding | 55.22m |
Free float | 52.45m |
P/E (TTM) | 34.27 |
Market cap | 2.02bn USD |
EPS (TTM) | 1.07 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 07:10 GMT.
More ▼
Announcements
- Supernus Announces Third Quarter 2024 Financial Results
- Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
- Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
- Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
- Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
- Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
- Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
- Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
- Supernus Announces Second Quarter 2024 Financial Results
More ▼